Insider Buying Week 08-28-26 My Wall of Worry Grows

For the past week, I’ve been preoccupied with variables entirely beyond my control. The list of concerns is only growing, and while I keep reminding myself that bull markets famously “climb a wall of worry,” I’m starting to wonder if my own optimism is just a case of cognitive dissonance.

1. RISING RATES: I’m fretting over rising interest rates. Risk-free Treasury bonds and bills are becoming stiff competition for equities by offering legitimate, inflation-adjusted returns. I’m not losing sleep over it, though, because a 5% taxable yield won’t satisfy the retirement needs of 95% of investors; they simply have to earn more to reach the finish line.
2. IRAN WAR: Then there is the conflict with Iran. I worry that rising gasoline prices will spark social unrest, fueling a false narrative of progress from the social democrats. Does anyone truly believe they will be helpful for the investor class? I try to steer clear of politics, but the threat of wealth expropriation through increased taxes never bodes well for the “haves,” and as always, the “have-nots” end up getting squeezed the hardest.
3. AI BACKLASH: I’m also concerned about the growing backlash against AI data centers and workplace automation. These technologies are the primary engines of GDP growth; without them, we risk stagnating in low-growth or declining industries.
4. GAMBLING MENTALITY: Compounding this is the pervasive “gambling mentality” infecting the markets. Between end-of-day options and an endless variety of levered ETFs, the focus has shifted from sound investing to instant riches. Prediction markets are just a symptom of a generation that views the traditional path to wealth as rigged, leaving them feeling as though they have no choice but to roll the dice.
5. The usual lack of screaming values in the large cap names that offer safety and yield.  They are mostly bid up at the historic tops of their range.

I’m sure I’ll find more to worry about soon, so stay tuned. For now, the Insomniac Hedge Fund Guy is fretting that he won’t make it to the end without taking a few risks of his own. If you’re looking for insider buys to help pad your returns, take a hard look at Dick’s Sporting Goods (DKS) following its recent earnings-related selloff. If you believe the conflict in the Middle East will persist and curtail global hydrocarbon supply, investigate the two oil and gas drillers and the pipeline company currently buying back massive amounts of their own stock. Remember, the stocks you overlook are often the ones that become the ten-baggers no one saw coming.

 

Name: Andrew Gundlach 
Position: Director
Transaction Date: 08-25-2026 Shares Bought: 10,000 shares an average price paid of $240.76 for Cost: $2,407,650

Company: Welltower Inc. (WELL)

Welltower Inc. is a major healthcare-focused real estate investment trust located at the heart of the burgeoning “silver economy.” The company specializes on senior housing and wellness communities throughout the United States, the United Kingdom, and Canada. Its portfolio includes over 2,500 communities that combine residential living with hotel-style services for older adults and mature renters. Welltower targets desirable markets with substantial demographic growth and operates through strategic partnerships based on data-driven investment decisions. The Welltower Business System, the company’s integrated operating platform, is intended to boost operational performance and promote long-term growth. The company’s strategy emphasizes disciplined capital allocation, effective property operations, and long-term per-share value development. Welltower Inc., founded in 1970 in Delaware, is headquartered in Toledo, Ohio.

Andrew Gundlach has served as an independent Director of Welltower Inc. since July 29, 2024, when he was appointed to the company’s Board of Directors. He joined the Board on the same date and serves on the Audit Committee and Investment Committee. Gundlach is the President and Chief Executive Officer of Bleichroeder LP, bringing nearly three decades of experience in investment management, corporate strategy, capital markets, and corporate governance. Earlier in his career, he held investment banking roles at Morgan Stanley and J.P. Morgan and has served on numerous corporate boards. He earned a Bachelor of Science in International Relations and Affairs and a Master of Science in International Trade and Economics from Georgetown University’s School of Foreign Service, along with an MBA from Columbia Business School.

Insomniac Hedge Fund Guy Opinion: Welltower is the best operator in healthcare real estate right now, full stop — margins, growth, and capital discipline all lead the peer group. But the stock knows it: trading near highs after a 57% run, it’s priced for the growth to keep compounding at an elevated clip, and my DCF says you’re paying close to fair value, not picking up a discount. Light short interest and a director buying shares are mild positives, not conviction signals. This is a hold for existing owners, and a wait-for-a-pullback name for new money — great business, but the entry price matters, and right now you’re not getting paid to take the valuation risk.  

Name: Kenneth S. Courtis
Position: Director
Transaction Date: 08-25-2026 Shares Bought: 5,000 shares an average price paid of $216.53 for Cost: $1,082,665

Company: Alpha Metallurgical Resources Inc. (AMR)

Alpha Metallurgical Resources, Inc. is a mining firm that produces, processes, and sells met and thermal coal in Virginia and West Virginia. The company offers metallurgical coal products. It runs nineteen operating mines and eight active coal processing and loading facilities. The company was formerly known as Contura Energy, Inc. before changing its name to Alpha Metallurgical Resources, Inc. in April 2017. Alpha Metallurgical Resources, Inc. was established in 2016 and is based in Bristol, Tennessee.

Kenneth S. Courtis has been serving as director of Alpha Metallurgical Resources Inc. since February 2021. He has also been chairman of Starfort Investment Holdings since 2009. Mr. Courtis has more than 30 years of experience in corporate finance, investments, and nearly every facet of the commodity sector. Throughout his career, he has served on the boards or advisory councils of several significant worldwide corporations. Mr. Courtis holds an undergraduate degree from Glendon College in Toronto and a master’s degree in international relations from Sussex University in the UK. He holds a master’s degree in business administration from the European Institute of Business Administration as well as a doctorate with highest distinction from Sciences Po in Paris.

Insomniac Hedge Fund Guy Opinion: Hold, leaning cautious — not a buy at $227. The insider buying is loud and the low-vol coal reserves are real quality, but the stock has rallied hard into a guidance cut, a net loss, and analyst price targets sitting 21% below the current price. A DCF built on realistic cash flow assumptions puts fair value closer to $90–$115, and with short interest running near 16% of float, this is a stock priced for a met-coal recovery that hasn’t shown up in the numbers yet. If the insiders are right and pricing snaps back, this squeezes higher fast — but chasing it here means betting against your own valuation math, not with it.

Name: Rajesh Kalathur
Position: Director
Transaction Date: 08-21-2026 Shares Bought: 2,829 shares an average price paid of $177.00 for Cost: $500,733

Company: American Tower Corp (AMT)

American Tower Corporation is a leading independent owner, operator, and developer of multitenant communication infrastructure, as well as one of the world’s largest real estate investment trusts. The corporation oversees a global portfolio of about 148,000 communication stations, which provide wireless networks and other connectivity services. Its infrastructure provides critical locations for telecommunications equipment, allowing mobile connectivity and the ongoing expansion of wireless networks. American Tower also manages a highly interconnected network of data center facilities in the United States, which exposes it to the expanding need for digital infrastructure and data connectivity. Its size and strategically located properties provide it a strong position in the global communications real estate market. American Tower Corporation, founded in 1995 in Delaware, is headquartered in Boston, Massachusetts.

Rajesh Kalathur has been an independent Director at American Tower Corporation since February 5, 2025, when he was elected to the company’s Board of Directors and nominated to the Audit Committee. He joined the Board on the same date and has over 27 years of worldwide leadership experience in finance, information technology, operations, and digital transformation. He earned a Bachelor of Science in Mechanical Engineering from the National Institute of Technology in Jamshedpur, a Master of Science in Industrial Engineering from the University of Alabama, and an MBA from the University of Chicago Booth School of Business

Insomniac Hedge Fund Guy Opinion: American Tower is a high-quality toll-road business trading at a fair-to-slightly-discounted price, with real cash flow, a Perfect10 composite score of +3.8 (Constructive), analyst consensus solidly bullish, and a director putting his own money on the table. The DISH churn hit and a weak real estate sector backdrop are legitimate near-term drags, but the CoreSite data center growth engine and disciplined portfolio management (the Canadian divestiture) suggest management is steering this ship well. This is a buy for patient investors who want durable, inflation-linked cash flow and are comfortable holding through REIT rate sensitivity — not a name for anyone chasing a quick pop.

Name: James A. Burke
Position: President and CEO
Transaction Date: 08-24-2026 Shares Bought: 2,000 shares an average price paid of $135.00 for Cost: $270,000

Company: Vistra Corp. (VST)

Vistra Corp. is an integrated retail electricity and power generation firm that serves and industrial consumers throughout the United States. The company operates a diverse portfolio of natural gas, nuclear, coal, solar, and battery energy storage plants, as well as providing electricity and natural gas through its retail division. Vistra is also involved in wholesale energy trading, fuel procurement, commodities risk management, and the decommissioning and reclamation of defunct power plants. Through its integrated business model, the company promotes dependable energy supply and the continued shift to cleaner energy sources. Vistra Corporation was founded in 1882 and is based in Irving, Texas.

James A. Burke has been President and CEO of Vistra Corp. since August 1, 2022, more than 18 years with Vistra and its predecessor firms, beginning in late 2004. When he took over as President and CEO on August 1, 2022, he joined the company’s Board of Directors as well. Throughout his tenure, Burke has held various top leadership positions, including Chief Operating Officer and President and Chief Financial Officer, bringing substantial operational and financial experience to the organization. He holds a bachelor’s degree in Economics and an MBA in Finance and General Management from Tulane University.

Insomniac Hedge Fund Guy Opinion: Perfect 10 composite score: +4.5 out of a possible +10 (Constructive) — Strong Buy analyst consensus, a 0.40 PEG ratio (a stock trading cheap relative to its growth rate) that screams undervalued-for-growth, and a CEO putting his own money on the table. The sector-wide utility drag and choppy GAAP earnings are the real drag on sentiment, not anything broken in the business. With a DCF in the $180–$210 range against a $139.81 price, and the AI power-demand catalyst still in its early innings, I’d call this a buy on weakness—the risk here is patience, not thesis. This is analysis for your own homework, not a recommendation — do your own due diligence before putting money behind it.

Name: Mark J. Barrenechea
Position: Director
Transaction Date: 08-27-2026 Shares Bought: 17,000 shares an average price paid of $130.72 for Cost: $2,222,240

Name: Sandeep Mathrani
Position: Director
Transaction Date: 08-26-2026 Shares Bought: 1,550 shares an average price paid of $128.89 for Cost: $199,783

Name: William J. Colombo
Position: Director
Transaction Date: 08-26-2026 Shares Bought: 6,100 shares an average price paid of $128.77 for Cost: $785,500

Name: Robert W. Eddy
Position: Director
Transaction Date: 08-26-2026 Shares Bought: 4,000 shares an average price paid of $128.69 for Cost: $514,780

Company: Dick’s Sporting Goods Inc. (DKS)

DICK’S Sporting Goods, Inc. is a leading omni-channel sports retailer in the United States, offering a diverse range of products for athletes and outdoor lovers. It sells sports equipment, fitness and golf gear, fishing supplies, athletic clothes, footwear, and accessories for running, basketball, tennis, hiking, and team sports. The company has several specialist retail concepts, including DICK’S Sporting Goods, Golf Galaxy, Public Lands, and DICK’S House of Sport. It also owns Foot Locker, which operates under many banners including Foot Locker, Kids Foot Locker, Champs Sports, WSS, and Atmos. Additionally, GameChanger offers digital youth sports services such as streaming, scheduling, communication, and scorekeeping. DICK’S Sporting Goods, Inc., founded in 1948, is headquartered in Coraopolis, Pennsylvania.

Mark J. Barrenechea has been an independent Director at DICK’S Sporting Goods, Inc. since February 2014, when he joined the company’s Board of Directors. He has been a Director since his appointment and currently chairs the Board’s Audit Committee. Barrenechea is a seasoned technology leader best recognized for his roles as CEO and CTO of OpenText Corporation, as well as President and CEO of Silicon Graphics International. His considerable experience in technology, digital transformation, corporate strategy, and worldwide operations adds significant value to DICK’S Sporting Goods’ board. He received a Bachelor of Science degree in Computer Science from Saint Michael’s College.

Sandeep Mathrani has been an independent director at DICK’S Sporting Goods, Inc. since September 22, 2020, when he was named to the company’s Board of Directors. He joined the Board in September 2020 and currently serves on the Audit Committee, having substantial experience in commercial real estate, business strategy, and executive leadership. Mathrani formerly served as WeWork’s CEO and then Chairman, as well as General Growth Properties and Brookfield Properties Retail Group, building a notable career in real estate. He graduated from Stevens Institute of Technology with a Bachelor of Engineering, Master of Engineering, and Master of Management Science degrees.

Robert W. Eddy has served as an independent Director of DICK’S Sporting Goods, Inc. since September 2023, when he was appointed to the company’s Board of Directors. He joined the Board of Directors on the same date and serves on the Governance & Nominating Committee and the Compensation Committee. Eddy is the Chairman, President, and Chief Executive Officer of BJ’s Wholesale Club Holdings, Inc., bringing extensive expertise in retail operations, finance, corporate strategy, and executive leadership. Before joining BJ’s in 2007, he spent more than a decade with PricewaterhouseCoopers LLP advising retail and consumer products companies. He earned a Bachelor of Science in Business Administration from Babson College.

William J. Colombo joined DICK’S Sporting Goods, Inc. in 1988 and has served as a Director since 2002, when he was elected to the Board of Directors. He has held that position consistently and was appointed Vise Chairman of the Board in February 2008, following his retirement as President and Chief Operating Officer. Throughout his executive career at DICK’S, Colombo held various critical leadership positions, including President and COO, Executive Vise President and COO, and President of dsports.com LLC, which aided the company’s operational growth and expansion. He attended William Paterson University in New Jersey, where he studied business administration.

Insomniac Hedge Fund Guy Opinion: Dick’s is a great retailer that just swallowed a mediocre one and choked on it publicly. The core banner is still one of the best-run operations in specialty retail — margins, comps, and format innovation are all working. But the Foot Locker deal turned a clean growth story into a leveraged bet on a turnaround management hasn’t proven it can execute, and the market punished that uncertainty with a 30% single-day gut punch. At $130–135, my rough DCF says the stock is priced for continued disappointment, not for a base case where synergies materialize on schedule. I’d call this a speculative buy for investors willing to underwrite Foot Locker execution risk over the next 12–18 months, not a broken business — but it’s not a name to back up the truck on until there’s evidence the bleeding in that segment has actually stopped. Watch the Q3 report in late November closely; that’s the print that decides whether this was a buying opportunity or a value trap.

Name: Edwin Roks
Position: President and CEO
Transaction Date: 08-25-2026 Shares Bought: 10,000  shares an average price paid of $111.77 for Cost: $1,117,700

Company: TTM Technologies Inc. (TTMI)

TTM Technologies, Inc. is a global technology company that specializes in mission systems, radio frequency components, microwave assemblies, printed circuit boards, and advanced substrates. It operates in three segments: aerospace and defense, commercial, and RF and specialty components. The company offers designed systems, RF and microwave assemblies, ceramic components, multi-chip modules, beamforming networks, and PCB design and testing services. Its technologies are useful for applications such as aircraft radar, marine surveillance, counter-drone systems, communications, air traffic management, and advanced air mobility. TTM serves the aerospace and defense, data centers, automotive, medical, industrial, and networking areas, serving OEMs, government agencies, electronics makers, and distributors globally. TTM Technologies, Inc., founded in 1978, is headquartered in Santa Ana, California.

On September 2, 2025, Edwin Roks, Ph.D., began serving as President and CEO of TTM Technologies Inc. At the same time, he was appointed to the Board of Directors as a Class II director, and he took on both positions upon joining the business. He holds a Ph.D. in Electronics and Semiconductor Physics from the University of Twente, a Master of Science in Electrical Engineering from Eindhoven University of Technology, a Bachelor of Science in Electrical Engineering from the College of Advanced Technology in the Netherlands, and has completed an Executive MBA Program at INSEAD.

Insomniac Hedge Fund Guy Opinion: TTMI is a growth story wearing a hardware manufacturer’s clothes — and right now, the growth is real. Revenue accelerating to 37% YoY, cash flow quality strong, a CEO buying shares with his own money into a dip, and a defense/AI double-tailwind that most industrials would kill for. The PEG ratio of 0.36 says the market hasn’t fully priced this growth yet, even with a P/E north of 50.

But this is not a “buy and forget” stock — it’s priced for perfection, customer concentration is a real risk in the AI order book, and 28 insider sales against 2 buys says plenty of executives are happy to take chips off the table even as the CEO adds his. I’d call this a buy for those willing to stomach volatility, not a widows-and-orphans holding — the fundamentals justify a position above the DCF floor near $140-165, but the Street’s $214 target requires the AI/defense boom to keep running hot with no hiccups. Size accordingly, and don’t mistake a hot growth quarter for a permanent moat.

Name: Scott L. Thompson
Position: CEO & President
Transaction Date: 08-27-2026 Shares Bought: 30,000 shares an average price paid of $62.84 for Cost: $1,885,314

Company: Somnigroup International Inc. (SGI)

Somnigroup International Inc., through its subsidiaries, designs, manufactures, distributes, and sells bedding products in the United States and abroad. It sells mattresses, foundations, adjustable foundations, and adjustable bases, as well as pillows and other accessories, under the Tempur-Pedic, Sealy, Stearns & Foster, and Sleepy’s labels. The company owns a number of retail brands, including Mattress Firm, Dreams, Tempur-Pedic retail locations, and SOVA; it also licenses the Sealy, Tempur, and Stearns & Foster names, as well as technologies and trademarks to other manufacturers. The company was previously known as Tempur Sealy International, Inc., but changed its name to Somnigroup International Inc. in February 2025. The corporation was founded in 1846 and is headquartered in Dallas, TX.

Somnigroup International Inc.’s President and CEO is Scott L. Thompson, who has been with the company since September 2015. He also became Chairman of the Board in September 2015 and has maintained both positions after the company’s rebranding to Somnigroup International. Under his leadership, the company has grown its direct-to-consumer business, solidified its market position, and finalized the game-changing acquisition of Mattress Firm. Thompson previously served as the President and CEO of Dollar Thrifty Automotive Group. He received a Bachelor of Business Administration from Stephen F. Austin State University.

Insomniac Hedge Fund Guy Opinion: Somnigroup is playing a roll-up game — buy distribution, buy components, squeeze competitors out of shelf space — and so far the balance sheet math checks out: cash flow is strong, leverage is coming down, and the CEO just backed the thesis with his own money near current levels. But organic growth has been dead flat for four years, and the entire growth story now rides on execution of two simultaneous integrations and $75 million of synergies that haven’t been proven yet. At ~$62.48 against a rough DCF band of $68–$78, this isn’t a screaming bargain, but it’s not stretched either — call it a cautious buy for patient investors willing to wait through integration noise, not a name to chase into the September 2 update call. This is analysis, not a recommendation — do your own homework before putting money behind it.

Name: Andrew Hudson La Force III
Position: Director
Transaction Date: 08-25-2026 Shares Bought: 20,000 shares an average price paid of $27.84 for Cost: $556,800

Company: Madison Air Solutions Corp. (MAIR)

Madison Air Solutions Corporation develops and sells indoor air quality products and solutions in the United States and abroad. It sells heating, air filtration and purification, air movement, and air conditioning products under the brands Reznor, AprilAire, Big Ass Fans, Nortek Air Solutions, and Roberts-Gordon. The company also offers related services like custom design, installation, repair, and maintenance. The company distributes via a variety of customer bases and sales channels, including direct sales to national, regional, and local businesses; manufacturers’ sales reps; distributors; and retail partners.  Madison Air Solutions Corporation was created in 2017 and is headquartered in Chicago, Illinois. Madison Air Solutions Corporation is a subsidiary of Madison Industries Holdings LLC.

Andrew Hudson La Force III has been an Independent Director of Madison Air Solutions Corp. since April 15, 2026, when he joined the board just before the company’s IPO. On the same day, he joined the company’s Board of Directors, where he chairs the Audit Committee and serves on the Compensation and Nominating Committees. Before joining Madison Air, La Force was President and CEO of W. R. Grace & Co. from 2018 to 2021, after previously serving as Chief Operating Officer and Chief Financial Officer. He graduated from Baylor University with a bachelor’s degree and received an MBA from Northwestern University’s Kellogg School of Management.

Insomniac Hedge Fund Guy Opinion: MAIR is a growth story wrapped around a legacy industrial category, and right now the fundamentals and the insider wallet are pointing the same direction. Nearly $840 million of insider buying with zero selling, a record backlog, and a chairman putting $620 million of his own cash into the ebm-papst deal — that’s not hedging, that’s conviction. The knock against it is real too: governance red flags (control concentration, internal-control weaknesses) and a valuation that already prices in a lot of good news. This is a speculative buy for investors comfortable with acquisition-integration risk and thin public-shareholder control — not a name for anyone who needs a clean governance profile or a bargain multiple. Do your own homework before following the insiders in; their $839 million doesn’t make it your money to lose.

Name: Brian J. Rosin
Position: CFO of IM8 (US) LLC
Transaction Date: 08-24-2026 Shares Bought: 23,100 shares an average price paid of $21.55 for Cost: $497,700

Name: Danny Sheng Wu Yeung
Position: Chief Executive Officer
Transaction Date: 08-20-2026 Shares Bought: 24,681 shares an average price paid of $20.34 for Cost: $501,998

Company: Prenetics Global Ltd. (PRE)

Prenetics Global Limited is a consumer health sciences firm that promotes human health and longevity through science-based goods and individualized health solutions. The company operates the IM8 brand, which specializes in consumer health and wellness products that promote healthy aging and overall well-being. It also runs CircleDNA, a consumer genetic testing platform that leverages advanced sequencing technology to give individualized reports on health, wellness, nutrition, and lifestyle. Prenetics principally serves consumers in the United States and Hong Kong, offering biotechnology, genetic insights, and consumer health products. Its goal is concentrated on making scientific health technology more accessible while also meeting the growing demand for individualized and longevity-oriented solutions. Prenetics Global Limited was founded in 2014 and has its headquarters in Quarry Bay, Hong Kong.

Brian J. Rosin joined Prenetics Global Ltd. in May 2026 as the Chief Financial Officer of IM8 (US) LLC, the company’s premium health and longevity brand. On May 14, 2026, he became Chief Financial Officer of IM8 (US) LLC, where he heads the finance group and is in charge of financial planning, capital allocation, investor relations assistance, and the financial infrastructure required to support IM8’s rapid global growth. Rosin was previously the Chief Financial Officer and Senior Vise President of e-Commerce Operations at Wellbeam Consumer Health, as well as the CFO of TruSkin, NATURELO Premium Supplements, and Rant, Inc. He graduated with honors from Northern Illinois University with dual bachelor’s degrees in economics and political science.

Danny Sheng Wu Yeung is the Co-Founder, CEO, and Chairman of the Board of Prenetics Global Ltd. He co-founded the company in 2014 and has served as CEO and Chairman of the Board since then, guiding Prenetics’ development into a global health sciences and consumer healthcare company. Prior to starting Prenetics, Yeung was the CEO of Groupon East Asia after Groupon acquired his firm, uBuyiBuy, and a founding partner at SXE Ventures. He has vast expertise as an entrepreneur and investor in healthcare and technology. He received a Bachelor of Science in Management Information Systems from the University of San Francisco.

Insomniac Hedge Fund Guy Opinion: This is a high-growth, high-conviction, high-risk name. The growth numbers are real and accelerating, insiders are buying with real money and zero selling, and the DCF and analyst targets both point meaningfully above the current price. But the company still isn’t profitable, recurring-revenue quality is unproven, and the entire valuation rests on one brand sustaining triple-digit growth in a category where moats are made of marketing budgets, not patents. I’d call PRE a speculative buy for investors who can stomach volatility — the insider buying and guidance raises tip the scale bullish, but this is a growth bet, not a value one, and it should be sized like one. Do your own diligence before acting on any of this — this is market analysis, not personalized investment advice.

Name: John T. Raymond
Position: Director
Transaction Date: 08-21-2026 Shares Bought: 26,626 shares an average price paid of $16.22 for Cost: $432,002 

Company: NGL Energy Partners LP (NGL)

NGL Energy Partners LP is a diversified energy firm that transports, and distributes crude oil, natural gas liquids, and generated water throughout the United States. The company operates via three segments: Water Solutions, Crude Oil Logistics, and Liquids Logistics, which provide critical infrastructure and services to energy producers, refiners, and industrial users. Its operations include water recycling and disposal, crude oil transportation and storage, and distribution of natural gas liquids via pipelines, terminals, railcars, and maritime export facilities. NGL Energy Partners LP was created in 1940 and is based in Tulsa, Oklahoma.

John T. Raymond has been a Director of the Board of NGL Energy LP since August 2013, when he joined the board of directors of the general partner. He is the founder, managing partner, and CEO of The Energy & Minerals Group (EMG), a private investment firm founded in September 2006, with decades of leadership experience in the energy and investment sectors. Prior to joining EMG, he held senior executive positions at Plains Resources Inc. and Plains Exploration and Production Company. He graduated from Tulane University’s A.B. Freeman School of Business with a Bachelor of Science in Management, concentrating in finance and accounting.

Insomniac Hedge Fund Guy Opinion: NGL has quietly transformed itself from a commodity-trading also-ran into a real produced-water infrastructure story, and the insider buying tells me people close to the business believe the growth is durable. But the stock already ran nearly 4x in a year, the PEG ratio says growth is richly priced, and net margins still trail the fee-based midstream peers it wants to be compared to. This is a hold, not a chase — I like the water-business thesis, but I’m not buying a name up 239% with a DCF that says fair value is already in the rearview mirror. Let the next couple of quarters prove the margin story before paying up further.

Name: Troy Edward Wilson
Position: President and CEO
Transaction Date: 08-24-2026 Shares Bought: 100,000 shares an average price paid of $12.39 for Cost: $1,239,000

Company: Kura Oncology Inc. (KURA)

Kura Oncology, Inc., is a clinical-stage biopharmaceutical firm that develops cancer treatments. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible, and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial that includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders, as well as additional next-generation menin inhibitors for us The corporation is headquartered in San Diego, California.

Troy Edward Wilson, Ph.D., J.D., co-founded Kura Oncology Inc. and has been President and CEO from its founding in August 2014. In March 2015, he was appointed Chairman of the Board, which gave him authority over both the company’s senior leadership and the board. Dr. Wilson is an experienced biotechnology entrepreneur who has founded and led several innovative oncology firms, including Intellikine, Araxes Pharma, Wellspring Biosciences, and Avidity Biosciences. He received his J.D. from New York University, as well as his Ph.D. in Bioorganic Chemistry and B.A. in Biophysics from the University of California, Berkeley.

Insomniac Hedge Fund Guy Opinion: This is a straightforward binary bet dressed up in an early commercial win. The Perfect10 read comes back Constructive at +2.5 — bullish analyst coverage (Strong Buy consensus, $32 target), a market-moving insider buy from the CEO, and real early revenue traction, offset by negative cash flow and a still-unprofitable balance sheet. Add in ~16% short interest and you’ve got a stock where two camps are placing very different bets on the same information.

I lean speculative buy, not a core holding—the CEO’s $2.35 million personal bet plus a genuine early commercial lead in a novel drug class is a combination I don’t dismiss lightly. But the real trial — literally — doesn’t read out until 2028, and a company burning $64 million a quarter with a single-drug, single-partner concentration profile is not a stock to bet the farm on. Size it like the high-risk, high-reward biotech it is, not like a blue-chip.

Name: Parsa Kiai 
Position: Director
Transaction Date: 08-26-2026 Shares Bought: 43,150 shares an average price paid of $12.26 for Cost: $529,157

Company: Medifast Inc. (MED)

Medifast, Inc., a health and wellness corporation based in the United States, specializes in weight loss, weight management, and healthy lifestyle solutions under the OPTAVIA brand. The company’s nutrition goods include protein shakes, bars, snacks, cereals, soups, oatmeal, desserts, and vitamin supplements. Its services combine organized meal plans with habit-based guidance and coaching to assist consumers in reaching and maintaining healthy weight goals. Medifast also offers individualized solutions, such as the OPTAVIA Optimization Plan and GLP-1 Nutrition Support Plan, which are intended to help with long-term weight management. The company primarily markets its products through e-commerce, catering to individuals seeking convenient, systematic methods to nutrition, weight management, and healthy living. Medifast, Inc., founded in 1980, is headquartered in Baltimore, Maryland.

Parsa Kiai has been an independent Director of Medifast Inc. since May 19, 2026, when he was elected to the company’s Board of Directors at the 2026 Annual Meeting of Stockholders after being nominated under a cooperation agreement with Steamboat Capital. He joined the Board on the same date and has over 20 years of experience in investment, corporate finance, capital allocation, and corporate governance. Kiai co-founded Steamboat Capital, a value-oriented investment business, in 2012 and serves as its Managing Partner and Chief Investment Officer. He received his undergraduate degree from Cornell University and graduated in 2003 before starting his career in investment banking at Goldman Sachs.

Insomniac Hedge Fund Guy Opinion: This is a battered turnaround story, not a broken company — the balance sheet is clean, insiders are buying with real money, and short interest near 17% of float means the bears are crowded into a trade that could snap back violently on good news. But the fundamentals are still falling: revenue is down 75% from peak with no confirmed bottom, and the entire business model is fighting a structural headwind from GLP-1 drugs that isn’t going away. I’d call this a speculative, high-risk watch — not a buy on fundamentals alone, but a name worth tracking closely given the insider conviction and the squeeze setup; I wouldn’t back up the truck until coach counts and revenue actually stabilize for a couple of consecutive quarters.

Name: Gregory Austin Ciongoli
Position: Director
Transaction Date: 08-26-2026 Shares Bought: 102,603 shares an average price paid of $9.25 for Cost: $949,381

Company: Regenxbio Inc. (RGNX)

REGENXBIO Inc. is a clinical-stage biotechnology firm that develops gene treatments to deliver functional genes to cells damaged by genetic diseases. Its programs are based on the unique NAV Technology Platform, which uses adeno-associated viral gene delivery technology. Key prospects include ABBV-RGX-314, which targets retinal illnesses like wet age-related macular degeneration and diabetic retinopathy; RGX-202, which targets Duchenne muscular dystrophy; and RGX-121 and RGX-111, which treat mucopolysaccharidosis. The business also licenses its NAV platform to biotechnology and pharmaceutical companies, which broadens its potential reach across numerous therapeutic areas. REGENXBIO has formed key alliances with AbbVie and Nippon Shinyaku to enhance specific gene therapy products and expand development globally. REGENXBIO Inc., founded in 2008, is headquartered in Rockville, Maryland.

Gregory Austin Ciongoli has been an independent Director of REGENXBIO Inc. since August 25, 2026, when he was named to the company’s Board of Directors. He joined the Board on the same day and was appointed to the Audit Committee, as well as the Nominating and Corporate Governance Committee. Ciongoli is the Founder and Managing Partner of Adiumentum Capital Management, having previously worked as a Partner at The Baupost Group for over 16 years, leading investments in healthcare and other areas. He has substantial experience with biotechnology investing, capital allocation, corporate governance, and strategic change. He received an A.B. from Princeton University’s School of Public and International Affairs and an MBA from Harvard Business School.

Insomniac Hedge Fund Guy Opinion: REGENXBIO is a science story wrapped in a lumpy, unpredictable income statement. The IP is real, the partner roster is blue-chip, and insiders — including a board member putting nearly a million dollars of his own money in this month — are buying at these levels. But a declining legacy royalty stream, a fresh clinical hold on a key program, and 14.5% short interest tell you the market isn’t convinced the good news outweighs the bad yet. I’d call this a speculative watch, not a conviction buy: worth a small position if you can stomach binary regulatory catalysts, but not a name to bet the farm on until RGX-121 clarity and the AbbVie trial data actually land. Do your own homework before touching this one — gene therapy stocks live and die on FDA letters, not spreadsheets.

Name: Tor Olav Troim
Position: Director
Transaction Date: 08-24-2026 Shares Bought: 200,000 shares an average price paid of $4.37 for Cost: $874,620

Company: Borr Drilling Ltd. (BORR)

Borr Drilling Limited provides offshore shallow-water drilling services to the oil and gas industries in the Americas, Southeast Asia, West Africa, the Middle East, North Africa, and Europe. It owns, contracts, and operates jack-up rigs for shallow-water operations, as well as providing related equipment and work crews for oil and gas drilling and workover activities in exploration and production. It caters to oil and gas exploration and production companies, including integrated oil companies, state-owned national oil enterprises, and independent oil and gas producers. The company was previously known as Magni Drilling Limited before changing its name to Borr Drilling Limited in December 2016. Borr Drilling Limited was established in 2016 and is headquartered in Hamilton, Bermuda.

Tor Olav Troim has served as a Director of Borr Drilling Ltd. since the company’s incorporation in 2016 and was one of its founders. He has also served as Chairman of the Board from August 2017 to September 2019 and again from February 2022 to September 2025. Trøim has more than 30 years of experience in the energy and offshore drilling industries, having previously held senior leadership positions, including CEO of Seadrill Ltd., Frontline Ltd., Golar LNG Partners LP, and DNO AS. He is also the founder of Magni Partners and serves on the boards of several international companies. He earned a Master of Science degree in Naval Architecture from the University of Trondheim, Norway.

Insomniac Hedge Fund Guy Opinion: This is a speculative buy for anyone comfortable with cyclical energy risk. The market is pricing Borr like the recent earnings miss was a fundamental problem; the cash flow, backlog, and insider activity all say it was an accounting artifact from a smart refinancing move. When a chairman personally buys $9.6 million of stock in two weeks while short sellers pile in from the other direction, my money’s on the guy who actually runs the company. Do your own homework here — offshore drilling can turn on a dime with oil prices — but the setup favors the bulls more than the tape currently suggests.